Ganciclovir Is Associated with Low or Undetectable Epstein-Barr Virus DNA Load in Cerebrospinal Fluid of Patients with HIV-Related Primary Central Nervous System Lymphoma

Bossolasco, Simona; Falk, Kerstin I.; Ponzoni, Maurilio; Ceserani, Norberto; Crippa, Fulvio; Lazzarin, Adriano; Linde, Annika; Cinque, Paola

doi:10.1086/499956

Cited by 55 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of ganciclovir has been shown to decrease the EBV DNA load in the CSF of patients with HIV-related PCNSL. This finding lends support to the hypothesis that EBV is replicating in HIV patients with PCNSL and therefore may be a therapeutic target (57).…”

Section: Treatment Of Aids-related Pcnslsupporting

confidence: 82%

Current Management of Primary Central Nervous System Lymphoma

Schultz

Bovi

2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Treatment Of Aids-related Pcnslsupporting

confidence: 82%

Current Management of Primary Central Nervous System Lymphoma

Schultz

Bovi

2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…One possible reason for the low prevalence was the undetectable CSF EBV-DNA load in two patients who had been occasionally treated with anti-herpetic therapy before and during the treatment of PCNSL, including acyclovir for genital herpes in one patient and gancyclovir for CMV retinitis in the other (17). A history of anti-herpetic therapy should be considered when interpreting the results of EBV-PCR.…”

Section: Discussionmentioning

confidence: 99%

Epstein-Barr Viral Load in Cerebrospinal Fluid as a Diagnostic Marker of Central Nervous System Involvement of AIDS-related Lymphoma

et al. 2013

View full text Add to dashboard Cite

Objective AIDS-related lymphoma (ARL) often involves the central nervous system (CNS). Although the diagnostic value of Epstein-Barr virus (EBV)-DNA in cerebrospinal fluid (CSF) in detecting HIV-positive primary CNS lymphoma (PCNSL) has been established, its usefulness for identifying CNS involvement of systemic ARL remains elusive. In this study, we evaluated the utility of the EBV-DNA load in CSF in identifying CNS involvement in patients with systemic ARL. Methods We retrospectively reviewed the clinical and pathological data of consecutive ARL patients managed at our clinic between January 1998 and June 2012. Sixty-two patients with ARL, including eight PCNSL patients and 52 systemic ARL patients, and 63 controls underwent CSF EBV-DNA load evaluations before receiving chemotherapy. ARL-related CNS involvement was defined as any lesion diagnosed histologically or radiologically as a lymphoma in the brain, meninges, spine, cranial nerves or oculus. Results A cut off value of 200 copies/mL predicted the presence of CNS lesions with a sensitivity of 70% and a specificity of 85% in both the PCNSL and systemic ARL patients, while a sensitivity of 75% and a specificity of 93% were obtained for systemic ARL. A cut off value of 2,000 (3.30 log) copies/mL provided the best specificity (100%), with a sensitivity of 50%. Conclusion Our results support the clinical utility of evaluating the quantitative EBV-DNA load in the CSF for the diagnosis of CNS involvement of systemic ARL as well as PCNSL.

show abstract

“…In patients with HIV-associated EBV(+) lymphomas, EBV DNA was detected in plasma or serum in all patients in two series, but was undetectable in the plasma of HIV(+) controls matched for CD4 count and HIV viral load (Fan et al 2005;Ouedraogo et al 2013). However, in EBV(+) primary CNS lymphoma (PCNSL), EBV DNA may be detected in the plasma in only a minority of patients and at low copy number (Bossolasco et al 2002(Bossolasco et al , 2006Fan et al 2005), perhaps reflecting a "brain-blood" barrier for tumor DNA.…”

Section: Ebv(+) Lymphomas and Lymphoproliferative Disordersmentioning

confidence: 99%

“…In HIV-PCNSL, EBV DNA is detected in cerebral spinal fluid (CSF) in over 75 % of patients, but does not correlate with EBV DNA copy number in plasma (Bossolasco et al 2002(Bossolasco et al , 2006. In patients with imaging studies showing central nervous system mass lesions, the presence of viral DNA in the CSF is viewed by many as adequate to establish a diagnosis of PCNSL.…”

Section: Other Body Fluidsmentioning

confidence: 99%

The Biology and Clinical Utility of EBV Monitoring in Blood

Kanakry

Ambinder

2015

Epstein Barr Virus Volume 2

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) DNA in blood can be quantified in peripheral blood mononuclear cells, in circulating cell-free (CCF) DNA specimens, or in whole blood. CCF viral DNA may be actively released or extruded from viable cells, packaged in virions or passively shed from cells during apoptosis or necrosis. In infectious mononucleosis, viral DNA is detected in each of these kinds of specimens, although it is only transiently detected in CCF specimens. In nasopharyngeal carcinoma, CCF EBV DNA is an established tumor marker. In EBV-associated Hodgkin lymphoma and in EBV-associated extranodal NK-/T-cell lymphoma, there is growing evidence for the utility of CCF DNA as a tumor marker.

show abstract

Ganciclovir Is Associated with Low or Undetectable Epstein-Barr Virus DNA Load in Cerebrospinal Fluid of Patients with HIV-Related Primary Central Nervous System Lymphoma

Cited by 55 publications

References 21 publications

Current Management of Primary Central Nervous System Lymphoma

Current Management of Primary Central Nervous System Lymphoma

Epstein-Barr Viral Load in Cerebrospinal Fluid as a Diagnostic Marker of Central Nervous System Involvement of AIDS-related Lymphoma

The Biology and Clinical Utility of EBV Monitoring in Blood

Contact Info

Product

Resources

About